Alcon Inc. - Registered Shares

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Geneva, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alcon, Inc. (ALC) CEO David Endicott on Q3 2020 Results - Earnings Call Transcript

Shares of Alcon (NYSE:ALC) rose 2.73% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 15.22% year over year to $0.39, which beat the estimate of $0.22.

Alcon: Q3 Earnings Insights

Alcon Inc. (ALC) CEO David Endicott on Q2 2020 Results - Earnings Call Transcript

Alcon Inc. (ALC) CEO David Endicott on Q1 2020 Results - Earnings Call Transcript

Alcon, Inc. (ALC) CEO David Endicott on Q4 2019 Results - Earnings Call Transcript

GlaxoSmithKline

The switch will increase the availability of pain and allergy drugs from GlaxoSmithKline and Alcon.

FDA Approves 3 Drugs for the Switch From Prescription to Over the Counter

News for Alcon Inc. - Registered Shares Stock (ALC)